Stock Events

Stock Events

IN8bio 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q1 2026
Q2 2026
Next
-0.53
-0.42
-0.32
-0.22
Expected EPS
-0.270038285
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-16.95MNet Income

Analyst Ratings

4.55Average Price Target
The highest estimate is 4.55.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 6JH.MU. It's not an investment recommendation.
MicroAlgo
5
MLGO
Global X NASDAQ 100 Covered Call
4
QYLD
Apple
3
AAPL
Realty Income
3
O

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is a biopharmaceutical company that competes with IN8bio in the development of cancer therapies, including cell therapies.
Novartis
NVS
Mkt Cap292.35B
Novartis is a global healthcare company that competes in the oncology sector, particularly in the development of innovative cancer treatments similar to IN8bio's focus.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb is involved in the discovery, development, and delivery of cancer treatments, competing directly with IN8bio in the oncology space.
Allogene Therapeutics
ALLO
Mkt Cap697.89M
Allogene Therapeutics is focused on the development of allogeneic CAR T therapies for cancer, competing in the same space as IN8bio.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is engaged in gene editing and cell therapy, including for cancer, which puts it in competition with IN8bio's cell therapy approach.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a large pharmaceutical company with a broad oncology portfolio, competing across various aspects of cancer treatment, including areas targeted by IN8bio.

About

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
Show more...
CEO
William T.
Employees
18
Country
United States
ISIN
US45674E1091

Listings

F
DE
6JH0.F
MU
DE
6JH.MU
STU
DE
6JH0.STU
MU
DE
6JH0.MU

0 Comments

Share your thoughts

FAQ

What is IN8bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange IN8bio stocks are traded under the ticker 6JH.MU.
When is the next IN8bio earnings date?▼
IN8bio is going to release the next earnings report on November 05, 2026.
What were IN8bio earnings last quarter?▼
6JH.MU earnings for the last quarter are -0.22 EUR per share, whereas the estimation was -0.3 EUR resulting in a +27.26% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is IN8bio revenue for the last year?▼
IN8bio revenue for the last year amounts to 0 EUR.
What is IN8bio net income for the last year?▼
6JH.MU net income for the last year is -16.95M EUR.
How many employees does IN8bio have?▼
As of September 04, 2026, the company has 18 employees.
In which sector is IN8bio located?▼
IN8bio operates in the Health & Wellness sector.
When did IN8bio complete a stock split?▼
The last stock split for IN8bio was on June 06, 2025 with a ratio of 1:30.
Where is IN8bio headquartered?▼
IN8bio is headquartered in NEW YORK, United States.